IR Menu

Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo.

Investor Presentation – January 2022

All Documents

Events

EVENTS & PRESENTATIONS

Investor Video

View Video

Press Releases

Jan 28, 2022
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation    read more...
Jan 24, 2022
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer    read more...
Jan 20, 2022
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia    read more...
Press Releases

INVESTOR RELATIONS +1 857-302-5189

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form